Top Banner
Chapter 38 Macrolides, Lincomycins and Polymycins
28

Chapter 38 Macrolides, Lincomycins and Polymycins.

Dec 28, 2015

Download

Documents

Carmella Carr
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Chapter 38 Macrolides, Lincomycins and Polymycins.

Chapter 38

Macrolides, Lincomycins

and Polymycins

Page 2: Chapter 38 Macrolides, Lincomycins and Polymycins.

大环内酯类药物 14元大环内酯类:红霉素、罗红霉素、克拉霉素、地红霉素

15元大环内酯类:阿奇霉素 16元大环内酯类:螺旋霉素、乙酰螺旋霉素、麦迪霉素、麦白霉素、罗他霉素、柱晶白霉素、交沙霉素、米欧卡霉素

Page 3: Chapter 38 Macrolides, Lincomycins and Polymycins.

Macrolides

First generation : 1950’s—erythromycin Second generation : 1970’s—claithromycin

azithromycin Third generation :

Page 4: Chapter 38 Macrolides, Lincomycins and Polymycins.

Common properties of Macrolides

Page 5: Chapter 38 Macrolides, Lincomycins and Polymycins.

Antibacterial activity First generation

Most G+ organisms: pneumococci, streptococci, staphylococci , diphtheriae etc

Part G- organisms:legionella (军团菌) ,bacillus pertussis( 百日咳 ), brucella( 布氏 ) etc

Others: mycoplasma( 支原体 ), chlamydia trachomatis( 沙眼衣原体 ), rickettsia( 立克次体 ), spirochete ,anaerobes etc.

Second generation More active on G- organisms

Page 6: Chapter 38 Macrolides, Lincomycins and Polymycins.

Mechanism of action Target

50s ribosomal RNA Mechanism

inhibition of translocation of mRNA

Page 7: Chapter 38 Macrolides, Lincomycins and Polymycins.
Page 8: Chapter 38 Macrolides, Lincomycins and Polymycins.
Page 9: Chapter 38 Macrolides, Lincomycins and Polymycins.

Mechanism of resistance

Production of inactivating enzymes Modification of the ribosomal binding site Active efflux system MLSR

Page 10: Chapter 38 Macrolides, Lincomycins and Polymycins.

Pharmokinetics

Absorption Erythromycin: not stable at acid pH New macrolides: stable po

Distribution Metabolism:

Erythromycin&clarithromycin: in liver Excretion

Erythromycin& azithromycin: bile Clarithromycin: kidney

Page 11: Chapter 38 Macrolides, Lincomycins and Polymycins.

Commomly used macrolides

Page 12: Chapter 38 Macrolides, Lincomycins and Polymycins.

Erythromycin

Antimicrobial activity Gram-positive organisms: pneumococci, stre

ptococci, staphylococci , diphtheriae etc Gram-negative organisms:legionella (军团菌) ,

bacillus pertussis( 百日咳 ), brucella( 布氏 ) ,

meningococci, diplococcus gonorrhoeae etc Others: mycoplasma( 支原体 ), chlamydia trach

omatis( 沙眼衣原体 ), rickettsia( 立克次体 ), spirochete ,anaerobes etc.

Page 13: Chapter 38 Macrolides, Lincomycins and Polymycins.

Erythromycin

Clinical uses As penicillin substitute in penicillin-allergic or

resistant patients with infections caused by staphylococci, streptococci and pneumococci

Pertussis , diphtheriae Legionella and mycoplasma pneumonia H.p infection

Page 14: Chapter 38 Macrolides, Lincomycins and Polymycins.

Erythromycin

Adverse reactions Gastrointestinal effects Liver toxicity Cardiotoxicity

Page 15: Chapter 38 Macrolides, Lincomycins and Polymycins.

Erythromycin Erythromycin lactobionate( 乳糖酸红霉素) erythromycin estolate (无味红霉素 )

erythromycin stearate( 硬脂酸红霉素) erythromycin ethylsuccinate (琥乙红霉素, 利君沙)

Page 16: Chapter 38 Macrolides, Lincomycins and Polymycins.

New macrolides antibiotics Advantage :

Broader spectrum, higher activity Orally effective High blood concentration Longer t 1/2

Less toxicity Mainly used in respiratory tract infection

Page 17: Chapter 38 Macrolides, Lincomycins and Polymycins.

Clarithromycin (甲红霉素 , 克拉霉素)

Has the strongest activity on Gram-positive bacteria, legionella pneumophila, chlamydia pneumoniae and H.p

Good pharmacokinetic property Low toxicity

Page 18: Chapter 38 Macrolides, Lincomycins and Polymycins.

Azithromycin ( 阿齐霉素 , 丽珠奇乐)

Has the strongest activity against mycoplasma pneumoniae (肺炎支原体)

More effective on Gram-negative bacteria Well tolerated T1/2 :35~48h once daily Mainly used in respitory tract infection

Page 19: Chapter 38 Macrolides, Lincomycins and Polymycins.

Roxithromycin (罗红霉素,严迪) 1987 France The highest blood concentration F 72%~85% Respiratory tract infection and soft tissue

infection Low adverse effects

Page 20: Chapter 38 Macrolides, Lincomycins and Polymycins.

Lincomycin and Clindamycin Antimicrobial activity

Gram-positive organisms Bacteroide fragilis and other anaerobes

Mechanism Binding to 50s ribosome subunit and inhibiting

protein synthesis Pharmacokinetics

Absorbed well Penetrate well into most tissues including bone

Page 21: Chapter 38 Macrolides, Lincomycins and Polymycins.

Clindaycin

Clinical uses Severe anaerobic infection Acute or chronical suppurative osteomylitis , arthrit

is caused by susceptive organisms especially Staphylococci aureus

Adverse reactions Gastrointestinal effects: severe diarrhea and pseud

omembranous enterocolitis caused by Clostridium difficile :vancomycin & metronidazole

Other :Impaired liver function , neutropenia

Page 22: Chapter 38 Macrolides, Lincomycins and Polymycins.

Polypeptide antibiotics

Vancomycin & TeicoplaninPolymyxinsbactitracin

Page 23: Chapter 38 Macrolides, Lincomycins and Polymycins.

Vancomycin

Mechanism of action Inhibit cell wall synthesis

Antimicrobial spectrum: Narrow spectrum, active only against gram-positi

ve bacteria paticularly staphylococci Pharmacokinetics

Poorly absorbed from intestinal tract, iv Excreted from glomerular filtration 90%

Page 24: Chapter 38 Macrolides, Lincomycins and Polymycins.

Vancomycin

Clinical uses Infection caused by MRSA, MRSE and penicillin-

resistant pneumococcus Treatment of antibiotic-associated enterocolitis ca

used by clostridium difficile po Adverse reaction

Ototoxicity & nephrotoxicity Red-man syndrome

Page 25: Chapter 38 Macrolides, Lincomycins and Polymycins.

Teicoplanin

Similar to vancomycin in mechanism and antimicrobial spectrum

Can be given im as well as iv Less adverse reactions

Page 26: Chapter 38 Macrolides, Lincomycins and Polymycins.

Polymyxins

Active only against gram-negative rods, particularly P.aeruginosa

Mechanism:increase permeability of cell membrane

Mainly used in P.aeruginosa infection when other drugs are resistant

Toxicity: nephrotoxicity & neurotoxicity

Page 27: Chapter 38 Macrolides, Lincomycins and Polymycins.

Baciteracin

Active against gram-positive bacteria Inhibit cell wall formation No cross-resistance with other agents Topical use only because of nephrotoxicity

Page 28: Chapter 38 Macrolides, Lincomycins and Polymycins.